HCPCS code Q4140: Biodfence billing, fee schedule, and coverage guidelines

Key Takeaways

HCPCS code Q4140 describes Biodfence, per square centimeter: a Level II Q-series code for a collagen-based bioengineered skin substitute billed by wound area

Q4140 is classified as a high-cost skin substitute under 2025 CMS rules; always pair it with a CPT application code (15271-15278) or the claim will deny

LCD L38018 governs Medicare coverage: chronic ulcers, diabetic foot wounds, and surgical wounds are covered indications; off-label diagnoses create denial risk

Pabau’s claims management software tracks wound measurements, links companion codes, and flags documentation gaps before submission

Skin substitute billing is one of the highest-denial categories in wound care. Understanding medical billing fundamentals for product codes like HCPCS code Q4140 is the difference between timely reimbursement and a stack of corrected claims.

HCPCS code Q4140 is the Level II code for Biodfence, per square centimeter. CMS assigns this code to a collagen-based bioengineered skin substitute applied to wounds requiring cellular or tissue support. It sits within the Q4100-Q4170 series of skin and soft tissue substitute Q-codes maintained by CMS and updated quarterly.

Biodfence product overview

Biodfence is a collagen-based skin substitute designed for use on chronic and acute wounds where the body’s own tissue repair is insufficient. Composed of a collagen scaffold (the exact composition should be confirmed against the manufacturer label or FDA clearance documentation), it provides a temporary structural matrix to support wound closure.

Clinical applications covered under Medicare’s LCD for skin clinic and wound care settings typically include chronic venous ulcers, diabetic foot ulcers, and post-surgical wounds that have failed to respond to standard wound care. The product is billed per square centimeter applied, so accurate wound measurement at the time of application is a clinical and billing requirement, not just a documentation preference.

Q4140 fee schedule and Medicare payment rates (2025/2026)

Medicare reimbursement for Q4140 is driven by revenue cycle management considerations specific to high-cost skin substitutes: the Average Selling Price (ASP) mechanism applies under 2025 CMS rules, meaning the payment rate fluctuates quarterly based on manufacturer-reported sales data. Published rates from payerprice.com and CMS fee schedule tools represent point-in-time figures; always confirm the current quarter’s ASP with your MAC before billing.

Payment rates differ by setting. A physician office (non-facility) bills Q4140 under the Physician Fee Schedule; a hospital outpatient department or ASC bills under the Hospital Outpatient Prospective Payment System (HOPPS). The two rates are not the same and using the wrong place-of-service code is a frequent audit trigger.

Use the CMS Physician Fee Schedule lookup to verify current payment rates for Q4140 by MAC jurisdiction and place-of-service indicator before billing.

High-cost vs low-cost skin substitute classification

The Consolidated Appropriations Act restructured how CMS classifies skin substitutes for payment purposes, likely effective with the 2025 HOPPS final rule. Under the revised framework, Q4140 (Biodfence) is classified as a high-cost skin substitute. This classification carries real payment implications: high-cost products are assigned to higher-weighted APC groups in the HOPPS setting, while low-cost products receive a separate, lower-weighted APC.

The threshold separating high-cost from low-cost is determined by CMS pricing data. Verify the current threshold against the CMS HOPPS final rule for the applicable year, as misclassifying a high-cost product as low-cost (or billing under the wrong APC) leads to underpayment or denial.

Streamline skin substitute billing with Pabau

Pabau’s claims management software tracks wound measurements, flags missing companion codes, and helps wound care practices submit cleaner claims with fewer denials.

Book a demo

Facility vs non-facility billing for Q4140

Place of service (POS) determines which fee schedule governs Q4140 reimbursement and which bill type codes apply. Getting this wrong is an audit risk, not just a payment delay.

Confirm bill type codes and revenue codes with your specific Medicare Administrative Contractor (MAC) before billing. Noridian, Novitas, CGS, and Palmetto GBA may have jurisdiction-specific guidance that supersedes general CMS tables.

CPT application codes to bill alongside Q4140

Q4140 is a product code. It cannot stand alone on a claim. According to CMS billing article 54117, the application of bioengineered skin substitutes requires a companion CPT application code from the 15271-15278 series. Submitting Q4140 without the correct application code is the single most common denial for this product.

ICD-10-CM diagnosis codes supported by Q4140

LCD L38018 specifies which diagnosis codes support coverage for skin substitute applications including Q4140. Billing Q4140 against an off-label ICD-10-CM code that is not LCD-listed creates an automatic denial. Insurance eligibility verification before application confirms the patient’s covered diagnosis is on the LCD-approved list.

Always select the most specific ICD-10-CM code available. Generic “unspecified” codes increase denial risk because they do not clearly demonstrate the wound characteristics required by LCD L38018.

Coverage guidelines and LCD L38018

LCD L38018 is the Local Coverage Determination governing Medicare coverage for skin and soft tissue substitute applications, including HCPCS code Q4140. Maintaining medical billing compliance for Q4140 requires documenting that coverage criteria are met before applying the product, not after the claim denies.

Covered indications under LCD L38018 generally include:

• Full-thickness or partial-thickness diabetic foot ulcers (DFUs) present for at least 30 days and unresponsive to standard wound care
• Venous leg ulcers that have failed conservative treatment (compression, wound dressings) for at least 30 days
• Chronic wounds meeting documented prior-treatment requirements
• Surgical wounds and acute traumatic wounds in select clinical scenarios

Payer-specific coverage notes

Commercial payers (BCBS, Aetna) follow their own medical policies for bioengineered skin substitutes, which may differ from LCD L38018 in covered diagnoses, the number of applications permitted per year, and prior authorization requirements. Prior authorization for Q4140 is payer-specific. Some MACs and commercial plans require it; others do not. Check the payer’s current policy and your MAC’s jurisdiction guidance before each application episode.

Documentation requirements for Q4140 billing

Proper documentation is the foundation of a clean claim submission for Q4140. CMS and LCD L38018 require specific elements in the medical record before and at the time of application.

• Wound measurements (cm²): document length x width of the wound surface in centimeters; this drives the Q4140 unit quantity billed
• Wound type and duration: confirm the wound type (DFU, venous ulcer, surgical wound) and how long it has been present
• Prior treatment history: at least 30 days of standard wound care with documented failure to respond
• Physician order: a signed order for the skin substitute application specifying the product and indication
• Medical necessity narrative: a note from the treating clinician explaining why Biodfence is appropriate for this specific patient
• Product label and lot number: document the product applied, including manufacturer and lot number, in the procedure note

Preparing a thorough superbill that includes Q4140, the companion application code, and all supporting ICD-10-CM codes helps ensure the claim package is complete before submission.

2025 CMS updates affecting Q4140

Several rule changes effective in 2025 directly affect skin substitute billing, including Q4140. Staying current with med spa compliance and wound care billing updates is essential for practices that apply skin substitutes regularly.

• High/low cost restructuring: the Consolidated Appropriations Act revised how CMS separates high-cost and low-cost skin substitutes into distinct APC groups under HOPPS; Q4140 (Biodfence) is likely classified as high-cost (verify against the current HOPPS final rule)
• ASP-based pricing: under 2025 rules, reimbursement for high-cost skin substitutes in non-facility settings is linked to the Average Selling Price; the rate updates quarterly, so last year’s fee schedule figures may no longer be accurate
• Q-code reassignments: CMS updates Q-code assignments quarterly; confirm that Q4140 remains the active code for Biodfence using the current CMS HCPCS code files
• Documentation requirements: the 2025 HOPPS final rule reinforced documentation standards for skin substitute medical necessity; prior treatment failure documentation remains mandatory

Related HCPCS skin substitute codes

Q4140 sits within a large family of skin substitute Q-codes. Coders often confuse adjacent codes when products share similar descriptions. Use the AAPC HCPCS code lookup or PGM Billing HCPCS lookup to verify the current code assigned to the specific product applied.

Never substitute one Q-code for another to achieve a higher reimbursement rate. Each code is product-specific; billing Q4140 for a different product constitutes upcoding and creates false claims liability.

Common billing errors with Q4140

No competitor reference page covers Q4140 billing errors in detail. These are the patterns that generate the most denials and the most rework for wound care billing teams. Effective denial management in healthcare starts with preventing these before submission, not chasing them after the fact.

• Missing companion application code: submitting Q4140 without a 15271-15278 CPT code on the same claim; this is the top denial reason and it is entirely preventable
• Wrong place-of-service code: billing POS 11 (physician office) for a procedure performed in a hospital outpatient department triggers payment under the wrong fee schedule and may constitute improper billing
• Insufficient wound measurement documentation: the units billed for Q4140 must equal the wound area in cm²; rounding up or estimating without a documented measurement creates an overpayment risk
• Off-label ICD-10-CM diagnosis code: pairing Q4140 with a diagnosis not listed in LCD L38018 produces an automatic denial with no appeal pathway unless the practice can demonstrate an exception
• Failing to document prior treatment failure: LCD L38018 requires evidence that standard wound care was attempted for at least 30 days; claims without this documentation are non-covered
• Using a retired or incorrect Q-code: CMS updates Q-code assignments quarterly; using an outdated code for Biodfence produces a code-not-on-file rejection

Review denial codes in medical billing to understand the specific remittance reason codes associated with these errors and how to structure effective appeals.

How Pabau supports skin substitute billing workflows

Practices that apply skin substitutes regularly need a system that keeps wound measurements, companion codes, and documentation requirements connected.

Pabau’s claims management software helps wound care practices track all the elements a Q4140 claim requires, from wound measurement logging through to claim submission. Linking treatment documentation to billing workflows reduces the gap where companion codes get missed and denial codes accumulate.

Managing medical spa compliance alongside wound care billing is simpler when one platform handles both. See how Pabau’s billing tools work for your practice by booking a demo.

Conclusion

Q4140 claims deny for predictable reasons. Missing the companion application code, mismatched place-of-service, insufficient prior-treatment documentation, and off-label diagnosis codes account for the vast majority of rejections on Biodfence applications.

Pabau’s claims management software connects wound measurement documentation, companion code tracking, and claim submission in one workflow, so the Q4140 pre-submission checklist runs as part of the process rather than as an afterthought. To see how it works for your wound care or skin clinic, book a demo.

Continue your research

Need to understand the full claims process before submitting Q4140? What is medical billing explains the end-to-end process from charge capture through remittance.

Getting denials on skin substitute claims? Denial management in healthcare covers root-cause analysis and appeal strategies for common remittance codes.

Want to understand how clearinghouses process wound care claims? Medical claims clearinghouse explains how electronic claims are validated, scrubbed, and routed to payers.

Frequently Asked Questions